There is accumulating evidence demonstrating that dysfunction of glutamatergic
neurotransmission, particularly via N-methyl-d-aspartate (NMDA) receptors, is involved in …

A growing body of evidence supports the idea that drugs targeting the glutamate system may
represent a valuable therapeutic alternative in major depressive disorders (MDD). The rapid …

Introduction: With regards to depression, the role of N-methyl-D-aspartate receptor (NMDA)
was pursued many years ago, mainly in the form of preclinical studies. Since then, there …

Mood disorders such as major depressive disorder and bipolar disorder are chronic and
recurrent illnesses that cause significant disability and affect approximately 350 million …

Major depressive disorder (MDD) is a common, recurrent mental illness that affects millions
of people worldwide. Accumulating evidence suggests that the N-methyl-D-aspartate …

Introduction: Mood disorders, including depression, are becoming increasingly prevalent in
the developed world. Furthermore, treatment of depression therapeutics, mainly influencing …

Introduction: Current antidepressant therapies exhibit low therapeutic efficiency and delayed
onset of antidepressant action. Thus, the search for better acting agents is a continuous …

Ample evidence indicates that glutamate homeostasis and neurotransmission are disrupted
in major depressive disorder; but the nature of this disruption and the mechanisms by which …

Although the biogenic amine models have provided meaningful links between clinical
phenomena and pharmacological management of mood disorders (MDs), the onset of …

Ketamine, functioning as a channel blocker of the excitatory glutamate-gated N-methyl-d-
aspartate (NMDA) receptors, displays compelling fast-acting and sustained antidepressant …